Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yipurun (Shanghai) Biotechnology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The Corina Intrauterine Drug-Eluting System is the company’s leading product, approved in China in 2024 for moderate-to-severe intrauterine adhesions, demonstrating statistically and clinically significant improvements in reducing adhesion recurrence and promoting endometrial growth at 60 days post-surgery in a randomized controlled registration trial[2][4][6][11].
- Therapeutic areas
- Women's Health
- Modalities
- DeviceDrug-device combinationSmall molecule (estradiol)
- Industry
- Implantable Medical Devices
02
Partnerships
Not specifically disclosed
Beyond the preview
Go deeper on Yipurun (Shanghai) Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yipurun (Shanghai) Biotechnology.